Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors (Q42171281)

17 October 2017

Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors (English)

1 reference

17 October 2017

1 reference

1 reference

Priscilla A Hollander

series ordinal

1

1 reference

PubMed ID

20463416

17 October 2017

Pamela Kushner

series ordinal

2

1 reference

PubMed ID

20463416

17 October 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

17 October 2017

Postgraduate Medicine

1 reference

17 October 2017

122

1 reference

17 October 2017

3

1 reference

17 October 2017

71-80

1 reference

Standards of medical care in diabetes--2010.

17 October 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Diabetes and fractures: an overshadowed association

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Diabetes Risk Perception and Intention to Adopt Healthy Lifest yles Among Primary Care Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

The role of gut hormones in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Comment on: Torii et al. (2009) Gene silencing of phogrin unveils its essential role in glucose-responsive pancreatic beta-cell growth. Diabetes 58:682-692.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2144

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2144

1 reference

17 October 2017

1 reference

PubMed ID

20463416